Effects of altered plasminogen activator inhibitor-1 expression on cardiovascular disease.
Effects of altered plasminogen activator inhibitor-1 expression on cardiovascular disease.
复制标题
DOI：
10.2174/138945011797635803
复制
发表时间：
2011-11
影响因子：
3.2
通讯作者：
Ploplis VA
中科院分区：
文献类型：
--
作者：
Ploplis VA
纤溶酶原激活物抑制剂-1 （PAI-1）是一种多功能蛋白，不仅能够通过抑制纤溶酶原激活来调节纤维蛋白溶解，而且还能够调节细胞信号事件，对细胞功能有直接的下游影响。血浆中这种蛋白水平的升高已被证明对心血管疾病的发生和发展有深远的影响。然而，许多研究的结果，特别是那些使用PAI-1缺陷小鼠模型的研究结果表明，它的功能是模糊的，有证据表明它既可以预防也可以增强各种疾病状态。许多生活方式的改变和药理学试剂已被确定可以调节PAI-1水平或功能。这些靶向功能的试剂主要集中在其调节纤溶蛋白形成的能力上，并已在血栓形成的体内模型中进行了研究。涉及细胞功能调节的进一步研究可能潜在地解决与该蛋白在调节心血管疾病中的功能相关的矛盾问题。
Plasminogen Activator Inhibitor-1 (PAI-1) is a multifunctional protein with the ability to not only regulate fibrinolysis through inhibition of plasminogen activation, but also cell signaling events which have direct downstream effects on cell function. Elevated plasma levels of this protein have been shown to have profound effects on the development and progression of cardiovascular diseases. However, results from a number of studies, especially those using PAI-1 deficient mouse models, have demonstrated that its function is ambiguous, with evidence of both preventing and enhancing various disease states. A number of lifestyle changes and pharmacological reagents have been identified that can regulate PAI-1 levels or function. Those reagents that target function are focused on its ability to regulate plasmin formation, and have been studied in vivo models of thrombosis. Further investigations involving regulation of cell function could potentially resolve paradoxical issues associated with the function of this protein in regulating cardiovascular disease.